Paper Details

  1. Home
  2. Paper Details

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.

Author: ArrietaA, AveryR K, ChouS, LeeI, MartyF M, StrasfeldL, TatarowiczW, VillanoS

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Maribavir (MBV), an investigational benzimidazole antiviral agent, holds promise for treating refractory cytomegalovirus (CMV) infections in transplant recipients. Previous studies have shown MBV's favorable safety profile, but further research is needed to determine its effectiveness in treating complex CMV syndromes.
Paper Details　
Original Abstract of the Article :
Despite advances in cytomegalovirus (CMV) prophylaxis and therapy, some transplant recipients still develop refractory CMV infections. Maribavir (MBV), an investigational benzimidazole antiviral agent, acts by a mechanism different from that of existing anti-CMV drugs. Previous Phase I and II studie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1399-3062.2010.00550.x

データ提供：米国国立医学図書館（NLM）

Combating Cytomegalovirus: A New Weapon in the Arsenal

Cytomegalovirus (CMV) infection, a common complication in transplant recipients, can be particularly challenging to treat, especially in cases of resistance to existing antiviral medications. This study explores the potential of maribavir (MBV), a novel benzimidazole antiviral agent, as a promising therapeutic option for refractory or resistant CMV infections in transplant recipients. The study examines the safety and efficacy of MBV in treating complex CMV syndromes, offering hope for patients struggling with this challenging infection.

Maribavir: A New Path for Treating Resistant CMV

The study highlights the potential of maribavir as an effective treatment option for refractory or resistant CMV infections, a significant breakthrough for patients struggling with this challenging complication. The favorable safety profile of maribavir further enhances its potential as a valuable addition to the existing arsenal of antiviral therapies.

A New Era for CMV Treatment: A Beacon of Hope

This study provides a beacon of hope for transplant recipients facing the challenge of refractory or resistant CMV infections. The promising results with maribavir suggest a new era for CMV treatment, potentially leading to improved outcomes and a better quality of life for these vulnerable patients.

Dr.Camel's Conclusion

This study explores the potential of maribavir as a promising treatment option for refractory or resistant CMV infections in transplant recipients, offering hope for a new era in CMV treatment. The study highlights the importance of developing novel antiviral therapies to combat the challenge of viral resistance, paving the way for improved outcomes for patients with CMV infection.

Date :
  1. Date Completed 2011-03-22
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

20682012

DOI: Digital Object Identifier

10.1111/j.1399-3062.2010.00550.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.